AXSM Q4 2019 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$8B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$24M

Net Income

-$25M

EPS (Diluted)

$-0.71

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$221M

Total Liabilities

$42M

Stockholders' Equity

$179M

Cash & Equivalents

$220M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$24M	-$9M	-158.5%
Net Income	-$25M	-$10M	-158.5%